ASX · CSL.AX
CSL Limited
A$200.37+A$2.87 (+1.45%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
Loading market information…
ASX · AVR.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 04:33 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Anteris Technologies Ltd’s quoted price sits in the lower half of its reported 52-week range, 42.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Anteris Technologies Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Anteris Technologies Ltd is a firm specializing in the structural heart domain. It is responsible for the production and distribution of ADAPT, a product based on regenerative tissue technology. The company is also actively involved in advancing DurAVR™, an innovative 3D single-component aortic valve specifically designed for treating aortic stenosis. Additionally, Anteris allocates resources to the research and development of regenerative medicines. Founded in 1999, the enterprise was formerly known as Admedus Limited until it rebranded to Anteris Technologies Ltd in May 2020. Its primary operations are conducted from its base in Toowong, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| A$2.13M-29.13% vs estimate |
| Q4 2023 | Apr 18, 2024 | -A$2.30 | A$1.76M |
|---|
| Q4 2023 | Feb 28, 2024 | -A$2.34 | A$4.00M-85.92% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$200.37+A$2.87 (+1.45%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
A$2.74+A$0.02 (+0.55%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.53% below the high.
A$196.97-A$0.12 (-0.06%)
Pro Medicus Limited’s quoted price sits in the upper half of its reported 52-week range, 27.82% below the high.
A$55.66+A$0.74 (+1.35%)
Ramsay Health Care Limited’s quoted price sits in the upper half of its reported 52-week range, 0.78% below the high.
A$19.47+A$0.40 (+2.07%)
Sonic Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 19.8% below the high.
A$0.91+A$0.03 (+3.07%)
PolyNovo Limited’s quoted price sits in the lower half of its reported 52-week range, 35.21% below the high.
A$5.54+A$0.19 (+3.55%)
Tetratherix Ltd.’s quoted price sits in the upper half of its reported 52-week range, 31.44% below the high.
A$0.55+A$0.01 (+1.87%)
Aroa Biosurgery Limited’s quoted price sits in the lower half of its reported 52-week range, 31.88% below the high.
